1. Home
  2. CSTL vs HELP Comparison

CSTL vs HELP Comparison

Compare CSTL & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$35.31

Market Cap

722.8M

Sector

Health Care

ML Signal

N/A

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

N/A

Current Price

$11.95

Market Cap

854.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CSTL
HELP
Founded
2007
N/A
Country
United States
Canada
Employees
N/A
50
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
854.9M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
CSTL
HELP
Price
$35.31
$11.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
11
Target Price
★ $45.11
$40.06
AVG Volume (30 Days)
254.6K
★ 1.6M
Earning Date
11-02-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $344,229,000.00
N/A
Revenue This Year
$8.41
N/A
Revenue Next Year
$10.30
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3.66
N/A
52 Week Low
$17.72
$3.76
52 Week High
$44.28
$15.15

Technical Indicators

Market Signals
Indicator
CSTL
HELP
Relative Strength Index (RSI) 63.06 49.77
Support Level $33.90 $11.68
Resistance Level $36.85 $14.75
Average True Range (ATR) 1.46 0.88
MACD -0.07 -0.22
Stochastic Oscillator 86.78 11.44

Price Performance

Historical Comparison
CSTL
HELP

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: